As of 2015, Mayo Clinic is conducting medical research programs designed to test particular drugs for patients with myelofibrosis and related conditions. The MPN Research Foundation funds research into myelofibrosis and other rare blood cancers at various institutions around the world.
One of the seven studies currently underway at Mayo Clinic involves a drug called Ruxolitinib. Researchers are attempting to find out if Ruxolitinib aids in reducing spleen size and minimizes side effects prior to a stem cell transplant procedure. The drug is FDA-approved for treatment of advanced myelofibrosis, but its use with stem cell transplantation is experimental.
The MPN Research Foundation funds clinical trials conducted by pharmaceutical companies and medical research organizations. The foundation is currently funding several studies that are testing a particular class of drugs called JAK2 inhibitors.